EGFR and Fanconi anemia: At the pre-weaning period, the SCB treatment significantly (p < 0.05) influenced 6 pathways (cell cycle, EGFR tyrosine kinase inhibitor resistance, bile secretion, Fanconi anemia pathway, mRNA surveillance pathway and oxytocin signaling pathway) in IlM and 5 pathways (caffeine metabolism, cAMP signaling pathway, steroid biosynthesis, proteasome and dopaminergic synapse) in RuD but had no impact on other GIT sites (Table 7) compared to CTL treatment.